|会社名||Novavax Inc. （ノババックス）|
|分野（sector）||Health Care ヘルスケア|
|産業（industry）||Biotechnology: Biological Products (No Diagnostic Substances)|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 ノババックス(Novavax Inc.)は臨床段階のバイオ医薬品会社である。同社は組換えナノ粒子ワクチン及びアジュバントの発見・開発・商業化に焦点を当てる。同社は組換えワクチンセグメントの開発を通じて事業を行っている。同社は、組換えナノ粒子ワクチン技術を用いて、既知疾患及び新興疾患に対応するワクチン候補物質を製造する。同社の製品パイプラインは、呼吸器合胞体ウイルス（RSV）、季節性インフルエンザ、パンデミックインフルエンザおよびエボラウイルス（EBOV）の臨床開発におけるワクチン候補の感染症に焦点を当てる。同社の人用鉛アジュバントであるMatrix-Mは、パンデミックインフルエンザH7N9ワクチン候補のフェーズI / II臨床試験にある。また、第I相臨床試験でEBOVワクチン候補と併せてMatrix-Mを試験している。同社は中東呼吸器症候群（MERS）を含む感染性疾患で、前臨床段階の追加プログラムを開発している。 ノババックスは、臨床段階の米国バイオ医薬品企業。組換えナノ粒子ワクチンおよび抗原性補強剤の発見、開発、商業化に従事する。呼吸器合胞体ウイルス、季節性インフルエンザと新型インフルエンザのための臨床開発などの感染症に対象を当て遺伝子組み換えによるワクチンを開発する。 Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.|
|本社所在地||20 Firstfield Road Garthersburg MD 20878 USA|
|代表者氏名||James Francis Young ジェームズ・フランシス・ヤング|
|代表者役職名||Independent Chairman of the Board|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Novavax Inc. revenues increased 65% to $20.4M. Net loss increased 3% to $90.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 16% to $83.5M (expense) Labor_Related Expenses in R&D increase of 18% to $5.6M (expense).|
Here Is Everything We Know About A COVID-19 Vaccine 2020/09/04 09:30:00 Zero Hedge
Here Is Everything We Know About A COVID-19 Vaccine Tyler Durden Fri, 09/04/2020 - 05:30 Under normal conditions, vaccines require as long as ten years of testing before they're approved by regulators, then it takes some more time for drug companies to produce and distribute the product to millions of patients around the world. Until very recently, the notion that the world could quickly develop and mass produce a vaccine for some new infectious disease within a matter of months seemed impossible. Of course, these aren't normal times. After unveiling the adenovirus-vector vaccine developed by the Gameleya Institute, Russian President Putin claimed that the vaccine was tested first on a small group of willing participants, including one of his own adult daughters. The implication was that traditional standards of medical ethics don't always apply during extreme situations. With vaccine news being the dominant story on Thursday , as investors around the world watched as the administration pushed the states to prepare to start distributing vaccine doses on an emergency basis come Nov. 1.
Novavax coronavirus vaccine appears safe in early trials; J&J COVID jab prevents severe illness in hamsters 2020/09/04 03:18:00 Times Now
Novavax says its potential coronavirus vaccine appears safe and elicits immune response in early human trials. J&J Ad26 vaccine protects against COVID-19 severe clinical disease in hamsters.
Coronavirus Latest: Thursday, September 3 2020/09/03 19:31:51 Yahoo Finance
On Thursday, Novavax published positive trial data, saying that its coronavirus vaccine candidate was ‘safe’ and ‘elected an immune response. This come as Sanofi and GlaxoSmithKline announced that they would start phase 1/2 of their adjuvanted vaccine. Yahoo Finance’s Anjalee Khemlani breaks down the latest news about the coronavirus on The Final Round.
Here's How Much Investing $1,000 In Novavax In 2010 Would Be Worth Today 2020/09/03 18:50:13 Benzinga
Investors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY ) total return for the decade was 250.5%. But there’s no question some big-name stocks did much better than others along the way. Novavax’s Difficult Decade: One poor performer of the last decade was biotech stock Novavax, Inc. (NASDAQ: NVAX ). Novavax spent much of the past decade under the radar, but its potential role in developing a vaccine for the COVID-19 coronavirus has gotten Wall Street’s attention in 2020. Prior to 2020, Novavax’s first big run on Wall Street came in 2015 when the company received an $89 million grant from the Bill & Melinda Gates Foundation to develop a vaccine for human respiratory syncytial virus, or RSV. The stock skyrocketed in 2015 after the company reported encouraging Phase 2 … Full story available on Benzinga.com
Positive results of Novavax COVID-19 vaccine published in major medical journal 2020/09/03 15:50:06 United Press International
Promising early-stage results for a potential COVID-19 vaccine from U.S. biotech firm Novavax have been published in a major peer-reviewed medical journal, an important phase in the approval process.
5 Stock Gainers for Friday: VBI Vaccines, Moderna, Novavax 2020/07/17 20:23:27 The Street
Stocks trading higher Friday include VBI Vaccines, Moderna, Novavax, Dynavax Technologies, and Quidel.
Trending Stock Market News Friday: Novavax, Ericsson, Boeing 2020/07/17 16:35:05 The Street
Novavax has gone from an afterthought to winning the biggest federal contract for a potential coronavirus vaccine.
Thinking about buying stock in Applied DNA Sciences, Microvision, Virgin Galactic, Blink Charging, or Novavax? 2020/07/17 13:31:00 PR Newswire
NEW YORK, July 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APDN, MVIS, SPCE, BLNK, and NVAX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
The vaccine story that's got everyone hooked 2020/07/17 03:33:43 Economic Times India
By Katie Thomas and Megan TwoheyIn late February, as the coronavirus spread around the world, Dr. Richard Hatchett, head of an international nonprofit that gives money to vaccine developers, got on an important call to discuss vaccine candidates after his plane touched down at London’s Heathrow Airport.Executives from the Bill & Melinda Gates Foundation, which helped found and finance the nonprofit, were on the line, enthusiastic about Novavax, a small biotech company they thought had the potential to develop a vaccine against the virus — fast.Although the company, based in Gaithersburg, Maryland, had never brought a vaccine to market in its 33-year history, these experts were optimistic about its technology, which uses moth cells to pump out crucial molecules at a much faster rate than typical vaccines — a major advantage in a pandemic.Hatchett’s organization, the Coalition for Epidemic Preparedness Innovations, would go on to invest $388 million in the company’s coronavirus vaccine.
How a Struggling Biotech Won $1.6 Billion to Make a Coronavirus Vaccine 2020/07/16 14:32:42 New York Times
Novavax just received the Trump administration’s largest vaccine contract. In the Maryland company’s 33-year history, it has never brought a vaccine to market.
Is Novavax (NVAX) Outperforming Other Medical Stocks This Year? 2020/03/02 16:30:11 Zacks Investment Research
Is (NVAX) Outperforming Other Medical Stocks This Year?
Thinking about buying stock in Canopy Growth Corp, General Motors, 3M, Novavax, or Vir Biotechnology? 2020/02/28 14:31:00 PR Newswire
NEW YORK, Feb. 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, GM, MMM, NVAX, and VIR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
The S&P 500 pulls off its quickest correction since the Great Depression 2020/02/28 14:21:32 Business Insider
The S&P 500 slipped into a correction after its 4.4% drop on Thursday, the dourest warning yet of the coronavirus' drag on US stocks. The six consecutive days of drops mark the benchmark index's quickest correction since 1933, when the S&P 500 plummeted 13.3% in two days, according to The Financial Times. A correction is defined as a 10% drop from a record high. The index's massive drop arrived as new virus deaths outside of China ratcheted up concerns that the outbreak would escalate to an economically crippling pandemic. Monitor the S&P 500 live here . The S&P 500 slipped through the week to post its fastest correction since the Great Depression as fears of a coronavirus-driven recession tore into markets around the world. The key index notched its biggest single-day drop since 2011 on Thursday after plunging 4.4%. The S&P 500 index wiped out its year-to-date gains after its Monday and Tuesday slumps and now sits 9% below where it closed December 31. The index's rapid downturn has also pushed the S&P 500 to 12% below its February 19 high.
Top Analyst Upgrades and Downgrades: Beyond Meat, CBOE, Chesapeake Energy, Dollar General, FLIR, Gilead, Lyft, Novavax, RBS, Uber, Zoom and More 2020/02/28 14:00:35 24/7 Wall street
A small group of scientists, execs, and VCs are $277 million richer as their companies race to create a coronavirus vaccine. Here are 7 who have raked in huge sums. 2020/02/28 13:24:17 Business Insider
Gilead , Moderna , and Novavax have all enjoyed massive gains after announcing potential coronavirus drugs, leading their executives, scientists, and early investors to rake in millions. The profits come as global markets tank on growing coronavirus concerns. Moderna has gained the most of the three since Friday's close, jumping 60% after announcing on Monday it submitted the first coronavirus vaccine for human trials. Here are the seven shareholders to collectively profit $277 million from the surging biotech stocks. Visit the Business Insider homepage for more stories. Three biotech stocks are surging on the possibility of coronavirus drugs and minting millions of dollars for their biggest shareholders. Gilead , Moderna , and Novavax have all outperformed the falling stock market in recent days as the three drug developers rush to introduce preventative vaccines and treatments. The coronavirus has caused more than 2,800 deaths and infected more than 82,000 since breaking out in Wuhan, China.
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 ノババックス NVAX Novavax Inc.）